Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Key Highlights
- ➤Zealand Pharma (ZEAL) opens 53,600-RSF research hub in Cambridge, Massachusetts
- ➤Cambridge hub expands research beyond peptides into hybrid modalities, including antibody peptide conjugates
- ➤Automation and advanced modeling aim to shorten development from idea to clinic
- ➤New site becomes Zealand Pharma’s primary U.S. address and expands its global research platform
Expert Statements
Adam Steensberg, President and Chief Executive Officer of Zealand Pharma
“Today, this research hub goes from vision to reality”
Adam Steensberg, President and Chief Executive Officer of Zealand Pharma
“In December, we presented our ambition to become a leader in obesity and metabolic health. This research hub is a commitment to achieve that ambition. Tomorrow, our scientists begin research here, joining colleagues in Copenhagen, and I am excited to see this long-term investment and bridging between two leading life science communities flourish.”
Utpal Singh, Executive Vice President and Chief Scientific Officer of Zealand Pharma
“The Cambridge hub will expand our platform and the biology we can modulate”
Utpal Singh, Executive Vice President and Chief Scientific Officer of Zealand Pharma
“This is integral to becoming a Generational Biotech. With automation and advanced modeling methodologies complemented with human intuition as the foundation of how we work here, we expect to move faster from idea to clinic, and Cambridge puts us shoulder to shoulder with some of the best scientific talent in the world to help us do it.”
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts * Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic health * Ribbon-cutting ceremony marks the official opening of the Company’s primary U.S. address, expanding Zealand Pharma’s global research platform Copenhagen, Denmark, and Boston, Massachusetts, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting ceremony. The site, first announced in March 2026, is now the primary U.S. address of Zealand Pharma.
The ceremony was led by Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, alongside Utpal Singh, Executive Vice President and Chief Scientific Officer, Christina Sonnenborg Bredal, Chief People Officer, and Martin Nicklasson, Chair of the Board.
Get started
Create a free account to read the full story.